Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 373

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 373
---
 as a result of a Superior Proposal or certain intervening events the failure to change its recommendation would be inconsistent with its fiduciary duties to Kineta’s stockholders under applicable Delaware law; |

| • |     | the requirement that, in the event of the termination of the Merger Agreement under certain circumstances, TuHURA will pay Kineta a termination fee of $1,000,000; and |

| • |     | Kineta’s right to terminate the Merger Agreement under certain circumstances, including in order to accept and enter into a definitive agreement with respect to an unsolicited Superior Proposal in certain circumstances, subject to providing TuHURA an opportunity to match such offer prior to taking such action and payment to TuHURA of a termination fee of $1,000,000 if the Merger Agreement is so terminated, which amount the Kineta Board of Directors believes to be reasonable under the circumstances, taking into account the range of such termination fees in similar transactions. |

With respect to the agreements related to the Asset Sales:

| • |     | the reasonableness of the nature of the liabilities to be assumed by each of HCRX, Pacira and GigaGen following consummation of the Asset Sales; |

227

| • |     | the number and the nature of the conditions to Kineta’s obligation to consummate the Asset Sales and the risk of non-satisfaction of such conditions as well as the likelihood that the Asset Sales will be consummated on a timely basis; and |

| • |     | the belief that the terms of each of the HCRX Asset Purchase Agreement, the Pacira Asset Purchase Agreement, and the GigaGen Agreement, including the parties’ representations, warranties and covenants, and the conditions to their respective obligations, are reasonable under the circumstances. |

The Kineta Board of Directors weighed these advantages and opportunities against a number of potentially negative factors in its deliberations concerning the Transactions, including:

| • |     | the risk to Kineta’s financial results in the event that one or both of the Transactions is not consummated, including the risk of Kineta needing to liquidate the company; |

| • |     | the risk that TuHURA’s financial performance may not meet Kineta’s expectations, including any contraction of trading multiples of TuHURA stock during the pendency of the Transaction; |

| • |     | the impact of external factors on TuHURA’s financial performance and/or trading multiples, including changes in regulation and other macroeconomic and